Promedior Announces Presentation Of Data At ARVO Demonstrating That PRM-151 (rhPTX-2) Suppresses Choroidal And Retinal Neovascularization
Promedior, Inc. today announced that data from preclinical studies of PRM-151 (recombinant human Pentraxin-2 (PTX-2)) will be presented at the Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO)...